As part of its business expansion activities, Partners4Access’ Sophie Schmitz will be attending industry group, BioIndustry Association (BIA)’s Summer Networking Reception on Thursday, July 12.
The event will take place at IET Savoy Place, London.
P4A became a member of BIA in June this year. BIA represents several stakeholders within the biosciences area from small clinical stage biotechs, large pharma corporations, academics and service providers to the biotech industry. Their members account for majority of biotech drugs currently in clinical development. BIA is a leading voice in highlighting the UK life science industry’s challenges in innovation, research and development.
Sophie Schmitz, Managing Partner said, “BIA’s event is a unique peer to peer networking forum enabling discussions in scientific advancements to corporate trends. With our focus on Orphan Drugs, Cell & Gene Therapy, this is a great opportunity for P4A to connect with world class research and development-led biotech companies.”
About Partners4Access:
P4A are specialists in orphan drug, cell and gene therapy access, partnering with the biotechnology industry to support launches worldwide. Focus areas include: orphan drug, cell and gene thearpy pricing and market access strategy; bespoke access roadmap development; rare disease foresights; evidence mitigation solutions and access team excellence training. As one of the only consultancies with comprehensive experience in orphan, cell and gene therapies, P4A are excellently placed to help clients successfully achieve access.
Through its initiatives, P4A are able to inform and shape the conversation around orphan drugs.
The team at P4A believe in striking an equilibrium in the rare disease world. That means helping drive access to the most appropriate treatments for patients and physicians, a fair return on investment for manufacturers at an affordable proposition for payers.
For more information, please email P4A at [email protected].
About the BIA
Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK’s position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people’s lives.
For further information, please go to www.bioindustry.org
